Background
Methods
Study design
Information sources and search strategy
Inclusion criteria
Study selection
Data extraction
Data analysis
Results
Selection of updated clinical guidelines
Characteristics of included clinical guidelines
n (%) | |
---|---|
Institution | |
Country | |
− North America | 37 (61.7) |
− Europe | 17 (28.3) |
− Asia | 4 (6.7) |
− International | 2 (3.3) |
Type of organisation | |
− Scientific/professional society | 28 (46.7) |
− Public institution | 26 (43.3) |
− Other (Federal institute, NGO) | 6 (10.0) |
Updated clinical guidelines | |
Scope | |
− Management | 25 (41.7) |
− Treatment | 15 (25.0) |
− Screening | 9 (15.0) |
− Diagnosis | 7 (11.7) |
− Prevention | 4 (6.7) |
Health topic | |
− Oncology | 16 (26.7) |
− Public health | 5 (8.3) |
− Internal medicine | 3 (5.0) |
− Mental health | 3 (5.0) |
− Others | 33 (55.0) |
Domain scores
Presentation of the updated CG
Updated CGs reporting each item n (%) | |
---|---|
Presentation of the updated clinical guideline | |
Item 1: The updated version can be distinguished from the previous version of the clinical guideline. | 60 (100) |
Item 2: The rationale for updating the clinical guideline is reported. | 37 (61.7) |
Item 3: Changes in the scope and purpose between the update and the previous version are described and justified. | 34 (56.7) |
Item 4: The sections reviewed in the updating process are described. | 40 (66.7) |
Item 5: Recommendations are clearly presented and labelled as new, modified, or not changed. Deleted recommendations are clearly noted. | 16 (26.7) |
Item 6: Changes in recommendations are reported and justified. | 23 (38.3) |
Editorial independence | |
Item 7: The panel participants in the updated version are described. | 57 (95.0) |
Item 8: Disclosures of interest of the group responsible for the updated version are recorded. | 58 (96.7) |
Item 9: The role of the funding body for the updated version is identified and described. | 30 (50.0) |
Methodology of the updating process | |
Item 10: The methods used for searching and identifying new evidence in the updating process are described. | 49 (81.7) |
Item 11: The methods used for evidence selection in the updating process are described. | 47 (78.3) |
Item 12: The methods used to assess the quality of the included evidence in the updating process are described. | 46 (76.7) |
Item 13: The methods used for evidence synthesis in the updating process are described. | 28 (46.7) |
Item 14: The methods used for external review of the updated version are described. | 23 (38.3) |
Item 15: The methods and plan for implementing the changes of the updated version in practice are described. | 23 (38.3) |
Item 16: The plan and methods for updating the new version in the future are reported. | 24 (40.0) |
Scorea
median (range) | Agreement ICC (95% CI) | |
---|---|---|
Domain | ||
− Presentation of the updated CG | 5.8 (1.7–10) | 0.854 (0.701–0.941) |
− Editorial independence | 8.3 (3.3–10) | 0.724 (0.534–0.860) |
− Methodology of the updating process | 5.7 (0–10) | 0.886 (0.771–0.952) |
Overall | 6.3 (3.1–10) | 0.880 (0.749–0.952) |
Editorial independence
Methodology of the updating process
Overall score
Overall scorea
median (range) |
p value
| |
---|---|---|
Institution | ||
Country | ||
− Europe | 8.1 (4.4–10.0) | 0.014 |
− International | 7.8 (6.9–8.8) | |
− Asia | 5.6 (3.8–6.3) | |
− North America | 5.6 (3.1–8.1) | |
Type of organisation | ||
− Public institution | 6.3 (3.1–10.0) | 0.617 |
− Scientific/professional society | 6.3 (3.1–8.8) | |
− Other (Federal institute, NGO) | 4.4 (3.8–8.1) | |
Updated clinical guidelines | ||
Scope | ||
− Diagnosis | 8.1 (5.0–9.4) | 0.097 |
− Prevention | 5.6 (4.4–6.3) | |
− Management | 6.3 (3.1–10.0) | |
− Treatment | 6.3 (4.4–8.8) | |
− Screening | 3.8 (3.1–8.1) | |
Health topic | ||
− Mental health | 6.9 (5.0–8.1) | 0.099 |
− Oncology | 6.3 (3.8–9.4) | |
− Internal medicine | 6.3 (5.6–8.1) | |
− Public health | 3.8 (3.1–3.8) | |
− Others | 6.3 (3.1–10.0) |